Recent developments in the treatment of rheumatoid arthritis.

Recent developments in the treatment of rheumatoid arthritis.

Bruce SP

Journal of pharmacy practice

2009

2009-02

The introduction of biologic response modifiers has revolutionized treatment approaches in rheumatoid arthritis. The ideal treatment approach to induce remission and minimize joint destruction is yet to be determined, however. The guidelines for the treatment of rheumatoid arthritis were updated in 2008. Evidence published recently may help to guide treatment decisions. In this review, advances in treatment approaches are discussed with added emphasis on the cardiovascular risks to this patient population. New data regarding the biologic response modifiers currently available in the US, abatacept and rituximab, are reviewed. Finally, emerging therapies are introduced, including tocilizumab. Investigational agents in development may provide additional options in the future treatment of rheumatoid arthritis.

Antibodies; Arthritis; Immunosuppressive Agents; Rheumatoid; Rheumatoid – Complications; Monoclonal – Administration and Dosage; Antirheumatic Agents – Administration and Dosage; Biological Response Modifiers – Administration and Dosage; Rheumatoid – Drug Therapy; Rheumatoid – Epidemiology; Rheumatoid – Physiopathology

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

65–74

1

22